Medicare Part D drug plans are expected to come with higher premiums and out-of-pocket deductibles, and some plans may pull ...

Treatments for achondroplasia, acute myeloid leukemia, familial chylomicronemia syndrome, immunoglobulin A nephropathy, and non-small cell lung cancer are under review.

The investigational agent is expected to provide protection against all known strains of seasonal influenza with a single dose.

Emalex received FDA authorization for an Expanded Access Program for its investigational Tourette syndrome drug. New Drug ...

The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for leniolisib for children aged 4 to 11 years with activated phosphoinositide ...

Provider directories for Medicare Advantage and AI prior authorization in select states are among the changes for 2026.

The FDA has extended the review period of the New Drug Application for tolebrutinib for the treatment of non-relapsing, secondary progressive MS and to slow disability accumulation independent of ...

The FDA has granted Fast Track designation to CS-1103 for the treatment of acute methamphetamine intoxication.

But plans can remove medications from their drug lists, add prior authorization restrictions and even increase deductibles ...

The FDA has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.